These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10621692)

  • 1. Patent term extension: an expensive and unnecessary giveaway.
    Gore A
    Health Aff (Millwood); 1982; 1(2):25-33. PubMed ID: 10621692
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of patent term restoration to small, high technology companies.
    Kiley TD
    Health Aff (Millwood); 1982; 1(2):46-52. PubMed ID: 7185722
    [No Abstract]   [Full Text] [Related]  

  • 3. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 4. Post-patent barriers to entry in the pharmaceutical industry.
    Scherer FM
    J Health Econ; 1985 Mar; 4(1):83-7. PubMed ID: 10271148
    [No Abstract]   [Full Text] [Related]  

  • 5. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ; Graham SJ
    Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract]   [Full Text] [Related]  

  • 6. "Obvious to try": a proper patentability standard in the pharmaceutical arts?
    Trask AV
    Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581
    [No Abstract]   [Full Text] [Related]  

  • 7. Patent term extension: an overreaching solution to a nonexistent problem.
    Engelberg AB
    Health Aff (Millwood); 1982; 1(2):34-45. PubMed ID: 10621693
    [No Abstract]   [Full Text] [Related]  

  • 8. Patents: a threat to innovation?
    Manocaran M
    Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 10. The importance of patent term restoration to pharmaceutical innovation.
    Huntt PB
    Health Aff (Millwood); 1982; 1(2):6-24. PubMed ID: 10324213
    [No Abstract]   [Full Text] [Related]  

  • 11. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
    Hemphill Kraus EJ
    N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478
    [No Abstract]   [Full Text] [Related]  

  • 12. The importance of patent term restoration to pharmaceutical innovation.
    Hutt PB
    Health Aff (Millwood); 1982; 1(2):6-24. PubMed ID: 7185724
    [No Abstract]   [Full Text] [Related]  

  • 13. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 14. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M
    N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract]   [Full Text] [Related]  

  • 16. Analyzing the protection scope limit for biosequence patent claims in China.
    Li W
    Nat Biotechnol; 2018 Sep; 36(9):811-813. PubMed ID: 30188533
    [No Abstract]   [Full Text] [Related]  

  • 17. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 18. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?
    Shah S; Silva MA; Malloy MJ
    Nat Biotechnol; 2016 Jul; 34(7):716-9. PubMed ID: 27404880
    [No Abstract]   [Full Text] [Related]  

  • 19. A day late and a few million dollars short.
    Goldenson D
    Nat Biotechnol; 2009 Jun; 27(6):538-41. PubMed ID: 19513055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.